CRO concept stocks strengthened collectively. As of press release, Viva Biotech (01873) rose 8.16% to HK$1.06; Zhaoyan Pharmaceutical (06127) rose 6.94% to HK$12.94; and Tiger Pharmaceuticals (03347) rose 6.83% to HK$35.2.
The Zhitong Finance App learned that CRO concept stocks were collectively strengthened. As of press release, Viva Biotech (01873) rose 8.16% to HK$1.06; Zhaoyuan Pharmaceutical (06127) rose 6.94% to HK$12.94; Tiger Pharmaceuticals (03347) rose 6.83% to HK$35.2; Pharmaceuticals (02269) rose 5.27% to HK$28.95; Kanglong Chemical (03759) rose 4.37% to HK$15.76.
According to the news, the final revised data recently released by the US Department of Commerce shows that GDP growth in the third quarter exceeded expectations and was revised down to 4.9%, and US inflation cooled down beyond expectations. Furthermore, the PCE price index fell short of expectations. Core PCE increased 3.2% year over year, the lowest since April 2021. Bosung Futures said that as US inflation continues to improve downward, the bank believes that interest rate cuts in the first quarter of 2024 will continue to ferment, and the US dollar index and US bond yields are expected to decline sharply at that time.
Pacific Securities recently indicated that the number of global and domestic financing incidents increased sequentially in November 2023. According to November healthcare financing data released by the Financial Services Association Venture Capital Connect, there were 109 financing incidents in the domestic healthcare sector in November 2023 (excluding IPOs, targeted increases, etc.), a year-on-year decrease of 31% and a year-on-year increase of 76%. The bank believes that with the gradual recovery of overseas demand, CXO companies with a high share of international business will take the lead in improving.